News
Agenus Inc. , a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab (BOT) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback